A New Monoclonal Antibody That Has The Potential To Neutralize All Viral Variants

Monoclonal antibodies offer what is now a proven way to prevent and treat Covid-19 infections. Until recently, antibodies were administered by intravenous (IV) injection, which limited their widespread use. Newer technologies allow antibodies to be administered intramuscularly or subcutaneously. Additionally, new data indicates that with minor modifications, monoclonal antibodies can provide protection for many months. These advances add to the ability to treat and prevent Covid-19.

One limitation of Covid-19 monoclonal antibodies is that virus variants can escape neutralization. Single point mutations or deletions in certain areas of the SARS-CoV-2 genome can eliminate or gravely reduce antibody potency. Here we describe a novel antibody: DH1047. The distinguishing characteristic of this antibody is that it is capable of neutralizing all known variants of interest and concern by targeting highly conserved epitopes.

Read the full article on Forbes

© William A. Haseltine, PhD. All Rights Reserved.